Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K reporting a private placement of 850 shares of Series A-2 Convertible Preferred Stock at $1,000 each, raising $850,000.
- Preferred shares carry a 10% annual dividend, payable in additional Series A-2 stock.
- Convertible into common at a fixed $4.49 price, with standard anti-dilution adjustments.
- Holders vote with common stock on an as-converted 1:1 basis.
- 1,000 shares authorized via a new Certificate of Designation; issuance closed on June 24 2025.
- Securities were sold under Rule 506(b); they are unregistered and subject to resale restrictions.
Items 1.01, 3.02, 3.03 and 5.03 disclose the agreement, equity issuance and charter amendment, all of which modify existing shareholder rights.